Učitavanje...

Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia

The management of chronic myeloid leukemia (CML) has been revolutionized by the discovery of tyrosine kinase inhibitors (TKIs) against BCR-ABL1 oncogenic fusion protein. Imatinib, the first BCR-ABL1 TKI, was introduced into clinical practice in the early 2000s. In the following years, the so-called...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncol Ther
Glavni autori: Tiribelli, Mario, Eskazan, Ahmet Emre
Format: Artigo
Jezik:Inglês
Izdano: Springer Healthcare 2019
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7360015/
https://ncbi.nlm.nih.gov/pubmed/32699984
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40487-019-00098-w
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!